ThurmanJE. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States. Endocr Pract, 2007; 13:672–678.
3.
LeeIT, LiuHC, LiauYJ, LeeWJ, HuangCN, SheuWH. Improvement in health-related quality of life, independent of fasting glucose concentration, via insulin pen device in diabetic patients. J Eval Clin Pract, 2009; 15:699–703.
4.
GnanalinghamMG, NewlandP, SmithCP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child, 1998; 79:59–62.
5.
KeithK, NicholsonD, RogersD. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila), 2004; 43:69–74.
6.
LteifAN, SchwenkWF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care, 1999; 22:137–140.
7.
AsakuraT, SeinoH, NakanoR, MutoT, ToraishiK, SakoY, KageyamaM, YohkohN. A comparison of the handling and accuracy of syringe and vial versus prefilled insulin pen (FlexPen)Diabetes Technol Ther, 2009; 11:657–661.
8.
MolifeC, LeeLJ, ShiL, SawhneyM, LenoxSM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther, 2009; 11:529–538.
9.
AlbanoS. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. The ORBITER Study Group. Acta Biomed, 2004; 75:34–39.
10.
RubinRR, PeyrotM. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care, 2004; 27:2495–2497.
11.
SummersKH, SzeinbachSL, LenoxSM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther, 2004; 26:1498–1505.
12.
StocklK, OryC, VanderplasA, NicklassonL, LynessW, CobdenD, ChangE. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin, 2007; 23:133–146.
13.
GraffMR, McClanahanMA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther, 1998; 20:486–496.
14.
LeeWC, BaluS, CobdenD, JoshiAV, PashosCL. Medication adherence, the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther, 2006; 28:1712–1725discussion 1710–1711.
